Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 18, 2019
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
Journal: The oncologist
Published: November 02, 2017
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Journal: The New England journal of medicine
Published: January 24, 2014
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Journal: The New England journal of medicine
Published: October 18, 2013
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 09, 2013
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
Journal: Clinical colorectal cancer
Published: December 28, 2012
Showing 1-6 of 6
Last Updated: 09/26/2026